NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 292 filers reported holding NOVOCURE LTD in Q1 2023. The put-call ratio across all filers is 0.47 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $438,117 | -90.8% | 27,128 | -76.5% | 0.00% | -90.0% |
Q2 2023 | $4,781,879 | -37.8% | 115,226 | -9.8% | 0.03% | -36.2% |
Q1 2023 | $7,682,524 | -22.8% | 127,744 | -5.9% | 0.05% | -13.0% |
Q4 2022 | $9,956,749 | -21.3% | 135,743 | -18.5% | 0.05% | -15.6% |
Q3 2022 | $12,651,000 | +20.2% | 166,502 | +9.9% | 0.06% | +42.2% |
Q2 2022 | $10,527,000 | -6.8% | 151,470 | +11.1% | 0.04% | -2.2% |
Q1 2022 | $11,291,000 | +51.3% | 136,280 | +37.1% | 0.05% | +7.0% |
Q4 2021 | $7,463,000 | -33.2% | 99,401 | +3.4% | 0.04% | -29.5% |
Q3 2021 | $11,165,000 | -47.9% | 96,106 | -0.6% | 0.06% | -55.8% |
Q2 2021 | $21,437,000 | – | 96,642 | – | 0.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |